肺腺癌中C—met表达与表皮生长因子受体-酪氨酸激酶抑Stain耐药的相关性  

Correlation between expression of C-met and epidermal growth factor receptor-tyrosine kinase inhibitor resistance in lung adenocarcinoma

作　　者：李雄峰 陈振文[1] 郗彦凤[2] 王晋芬[2] 徐义荣[1] 步鹏[2] 郭江红[2] 

机构地区：[1]山西医科大学汾阳学院病理学教研室,032200 [2]山西省肿瘤医院病理科,太原030013

出　　处：《肿瘤研究与临床》2018年第1期1-6,共6页Cancer Research and Clinic

基　　金：山西省自然科学基金（2011011038-1、2012011038-4）

摘　　要：目的 检测肺腺癌中C-met蛋白表达和基因扩增情况,分析其与表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）耐药和患者预后的关系.方法 选取2011年1月至2013年5月山西省肿瘤医院120例肺腺癌患者肿瘤组织,应用免疫组织化学（IHC）染色和荧光原位杂交（FISH）技术检测C-met蛋白表达和基因扩增情况,并对所有患者进行随访.分析C-met表达与临床病理特征、EGFR-TKI耐药和预后的关系.结果 120例肺腺癌组织中C-met蛋白高表达与基因扩增发生率分别为17.50％（21/120）、10.83％（13/120）.80例接受EGFR-TKI治疗的患者中,耐药患者C-met蛋白高表达发生率为30.43％（14/46）,高于未耐药患者的11.76％（4/34）,差异有统计学意义（χ2=3.908,P=0.048）;耐药患者C-met基因扩增率为19.57％（9/46）,高于未耐药患者的2.94％（1/34）,差异有统计学意义（P=0.038）.46例耐药患者中,C-met蛋白表达与基因扩增呈正相关（r=0.388,P=0.008）,但未接受EGFR-TKI治疗的40例患者中,C-met蛋白表达与基因扩增无相关性（r=0.279,P=0.081）.C-met蛋白高表达与患者年龄、病理分级、临床分期有关（均P〈0.05）;C-met基因扩增与临床分期有关（P=0.036）.Cox多因素回归分析结果表明C-met基因扩增是影响预后的独立因素（P=0.034）.结论 C-met蛋白表达和基因扩增是EGFR-TKI耐药的危险因素,基因扩增提示预后不良,可作为预后评估的一个指标.Objective To detect C-met protein expression and gene amplification in lung adenocarcinoma, and to analyze their relationship with epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI） resistance and prognosis. Methods A total of 120 cases of lung adenocarcinoma diagnosed in Shanxi Provincial Cancer Hospital from January 2011 to May 2013 were selected. The expressions of C-met protein and C-met gene amplification were conducted by immunohistochemistry （IHC） method and fluorescence in situ hybridization （FISH）, and all patients were followed up. The relationship between the expression of C-met protein and gene amplification with clinicopathological features and EGFR-TKI resistance and prognosis were analyzed. Results The high expression of C-met protein and gene amplification in 120 tissues were 17.5 % （21/120）, 10.83 % （13/120）. Of the 80 patients treated with EGFR-TKI, the incidence of C-met protein high expression was 30.43 % （14/46） in patients with drug resistance, which was significantly higher than that in patients without drug resistance （11.76 %, 4/34）, the difference was statistically significant （χ2= 3.908, P= 0.048）. The rate of C-met gene amplification was 19.57 % （9/46） in patients with drug resistance,which was significantly higher than that in patients without drug resistance （2.94 %, 1/34） the difference was statistically significant （P= 0.038）. The expression of C-met protein in 46 patients with drug resistance was positively correlated with gene amplification （r= 0.388, P= 0.008）, but in 40 patients without TKI, the expression of C-met protein was not correlated with gene amplification （r=0.279, P=0.081）. The high expression of C-met protein was correlated with age, pathological grade and clinical stage （all P〈0.05）, while C-met gene amplification was related to clinical stage （P=0.036）. Cox regression analysis suggested that C-met gene amplification was an independent prognostic factor （P= 0.034）. Conclusions C-m

关 键 词：肺肿瘤 原癌基因蛋白质C-MET 受体 表皮生长因子 酪氨酸激酶抑制剂 预后 抗药性 肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]